

2026 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Alexis K. Kuhn, PharmD, BCOP	Peer Reviewer	1. Amgen, Jazz Pharmaceuticals, Sanofi Genzyme Inc., Syndax Pharmaceuticals	1. Advisory Board Participation	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Jazz Pharmaceuticals ended in November 2024 Amgen ended in February 2025 Sanofi Genzyme ended in March 2025 Syndax Pharmaceuticals ended in April 2025 All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Alison Carulli, PharmD, BCOP	Peer Reviewer	1. Stemline Therapeutics	1. Non-CE Consulting	All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Aliyah Baluch, MD	Faculty	No relevant financial disclosures	N/A	N/A
Alyson Vezina	Planning Committee	No relevant financial disclosures	N/A	N/A
Alyssa Donadio, PharmD, BCPS, BCOP	Planning Committee	1. Genentech	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Genentech ended in April 2025 All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.
Amanda Strommen, PharmD, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A
Amber Clemmons, PharmD, BCOP, FHOPA	Faculty	No relevant financial disclosures	N/A	N/A
Anand Srinivasan, MBBS	Faculty	No relevant financial disclosures	N/A	N/A
Andrea Fadel	Planning Committee	1. Iovance	1. Non-CE Speakers Bureau	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Iovance ended in February 2025

2026 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
				All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.
Andrew Artz, MD	Faculty	1. CSL Vifor, Daiichi Sankyo	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> ▪ CSL Vifor ended in October 2025 Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Ashley Jones	Planning Committee	No relevant financial disclosures	N/A	N/A
Ashley Smeaton, MHA	TFF Staff	No relevant financial disclosures	N/A	N/A
Bhagirathbhai Dholaria, MD	Peer Reviewer	1. ADC Therapeutics, Arivan Research, AstraZeneca, Autolus, Caribou, Gilead, GSK, Janssen, MJH BioScience, Poseida, Roche 2. Adicet, Allovir, Angiocrine, Atara, BMS, Janssen, MEI, Moleulcar Template, Orcabio,	1. Non-CE Consulting 2. Contract Research	All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.

2026 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
		Pfizer, Poseida, Wugen		
Binni Kunvarjee, PharmD, BCOP	Faculty	1. Wolters Kluwer (Lexi UTD)	1. Non-CE Consulting	Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Breana Goscicki, PharmD, BCPPS	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Brian Shaffer	Peer Reviewer	1. Gamida Cell 2. Genentech, Incyte	1. Non-CE Consulting 2. Contract Research	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Gamida Cell ended in November 2025 All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Cameron Ninos, PharmD, BCOP	Faculty	1. Eli Lilly	1. Stock ownership of a publicly traded company	Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Christina Ferraro	Faculty	1. Incyte, Sanofi	1. Non-CE Consulting	Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Christine Duncan, MD	Faculty	1. Aspen NeuroScience, Beam Therapeutics, Gamida Cell, Sanofi, Viacord	1. Non-CE Consulting	Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Daniel Olson, MD	Faculty	1. BMS, Deciphera, Immunocore,	1. Non-CE Consulting	Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not

2026 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
		lovance, Replimune, Springworks 2. Astellas, Bayer, Chimeric, Context Therapeutics Immatics, Immunocore, Immuneering, InhibRx, Takeda, TScan	2. Contract Research (site-PI)	commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Denae Beckman	Planning Committee	No relevant financial disclosures	N/A	N/A
Elizabeth DiMaggio, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Emma Sheldon	Planning Committee	No relevant financial disclosures	N/A	N/A
Elizabeth (Bettina) Zerante, APP	Faculty	No relevant financial disclosures	N/A	N/A
Forat Lutfi, MD	Faculty	1. ADCT Therapeutics	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> ADCT Therapeutics ended in May 2024 Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Haedyn Smith	ASTCT Staff	No relevant financial disclosures	N/A	N/A
Heather Tarbox, MPH	TFF Staff	No relevant financial disclosures	N/A	N/A

2026 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Hemalatha Rangarajan, MD	Faculty	1. Medexus Treosufan, Vertex	1. One-time consultancy	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Medexus Treosufan ended in June 2024 Vertex ended in November 2024 Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Jason Ernstberger, PharmD	Faculty	No relevant financial disclosures	N/A	N/A
Jeanne Noonan McCarthy-Kaiser	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Jeff Kaiser, PharmD	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Jennifer Collins, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Jinjoo Kang, PharmD, BCPS	Planning Committee	No relevant financial disclosures	N/A	N/A
Jonathan Lambird, MD	Planning Committee	No relevant financial disclosures	N/A	N/A
Julie Guglielmo, PharmD, BCOP	Peer Reviewer	1. Sanofi	1. Non-CE Speakers Bureau	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Sanofi ended in August 2025 All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Katie Karkowski, PharmD, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A
Kendall Shultes, PharmD, BCOP	Planning Committee Chair	No relevant financial disclosures	N/A	N/A

2026 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Kristina Nelson, PharmD	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Kun (Peter) Lin	Planning Committee	No relevant financial disclosures	N/A	N/A
Lara Abousamra	Peer Reviewer	1. Incyte	1. Non-CE Consulting (Advisory Board)	All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA	Faculty	No relevant financial disclosures	N/A	N/A
Leslie Lehmann, MD	Peer Reviewer	1. Vertex Pharmaceuticals Incorporated Heme Business Unit	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Vertex Pharmaceuticals ended in July 2025 All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Liz Stockton	ASTCT Staff	No relevant financial disclosures	N/A	N/A
Lydia Boyce	ASTCT Staff	No relevant financial disclosures	N/A	N/A
Mallori Anderson, PharmD	Planning Committee	No relevant financial disclosures	N/A	N/A
Mariam Nawas, MD	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Mary Catherine (Catie) Cash, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Mary McGann, PharmD, BCOP	Planning Committee	1. Sanofi	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Sanofi ended in February 2024

2026 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
				All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.
Melani Rudisill	Peer Reviewer	1. Novartis	1. Advisory Board Member	All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Michael Williams	Planning Committee	No relevant financial disclosures	N/A	N/A
Michelle Skinner	Planning Committee	No relevant financial disclosures	N/A	N/A
Molly Gallogly, MD, PhD	Peer Reviewer	1. Eli Lilly, Incyte 2. Eli Lilly, Incyte	1. Non-CE Speakers Bureau 2. Non-CE Consulting	All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Molly Schiffer, PharmD, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A
Naresh Bumma	Peer Reviewer	1. Janssen 2. Alexion, BMS, Janssen, Regeneron	1. Non-CE Consulting 2. Contract Research	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Janssen ended in May 2025 All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Rahul Banerjee	Peer Reviewer	1. Abbvie, Adaptive Biotech, BMS, Caribou Biosciences, Genentech, Gilead, GSK, Janssen, Karyopharm, Legend	1. Non-CE Consulting	All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.

2026 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
		Biotech, Pfizer, Sanofi, SparkCures 2. Abbvie, BMS, Janssen, Novartis, Pack Health, Prothena, Sanofi	2. Contract Research	
Rebecca Gonzalez, PharmD, BCOP	Faculty	1. Orca Bio	1. Advisory Board	Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Samantha Maples	Planning Committee	1. Bristol Myers Squibb	1. Non-CE Consulting	All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.
Sara Leidy, PharmD	Planning Committee	No relevant financial disclosures	N/A	N/A
Shatha Farhan, MD	Faculty	No relevant financial disclosures	N/A	N/A
Stephanie Fooks-Parker MSW, LSW, OSW-C	Faculty	1. Vertex Pharmaceuticals	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Vertex Pharmaceuticals ended in December 2024 Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Susie Long, PharmD	Faculty, Planning Committee	1. McKesson Corporation	1. Non-CE Consulting	All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.

2026 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
				Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Teresa Rushing, PharmD, BCPS, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Terri Lynn Shigle, PharmD, BCPS, BCOP	Peer Reviewer	1. Sanofi	1. Non- CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> ▪ Sanofi ended in June 2025 All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Tiba Al Sagheer, PharmD, BCOP, BCACP	Peer Reviewer	1. Eli Lilly, Sanofi	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> ▪ Eli Lilly ended in April 2024 ▪ Sanofi ended in March 2025 All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.
Tiffany Harmer, BSN, RN	Faculty	No relevant financial disclosures	N/A	N/A
Vera Pervitsky, PharmD, BCOP, BCPS	Planning Committee	No relevant financial disclosures	N/A	N/A